Skip to main
STIM

Neuronetics Inc (STIM) Stock Forecast & Price Target

Neuronetics Inc (STIM) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Neuronetics is expected to have a strong revenue growth in the coming years due to their expansion into the fast-growing psychedelic therapy market and their effective treatment device, NeuroStar. Despite facing challenges, the company has implemented measures to improve operations and has acquired Greenbrook TMS to enhance their capabilities. With projected revenue of $161M in 2026, the company has potential for growth and is a strong competitor in the market against companies like BrainsWay and COMPASS Pathways.

Bears say

Neuronetics is facing significant obstacles in their transition to becoming a key player in interventional psychiatry, including difficulties in scalability and awareness among providers about their non-invasive alternative treatment option. Additionally, their reliance on a treatment session model has limited their reach and profitability, and they may need to raise additional capital in the near term. While they have a large market opportunity, their operating losses are expected to continue and there are risks associated with competition and alternative therapies.

Neuronetics Inc (STIM) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neuronetics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neuronetics Inc (STIM) Forecast

Analysts have given Neuronetics Inc (STIM) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Neuronetics Inc (STIM) has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neuronetics Inc (STIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.